The problem that starts every project
Teams planning preclinical or clinical gastroenterology work face a repeated mismatch: lab teams or clinical investigators expect clean endpoints and clear inference, while many vendors treat biostatistics as a checkbox rather than a partner; that’s why groups often search specifically for a gastroenterology CRO with statistical depth. Projects derail when sample-size assumptions clash with biological variability, analysis plans lack reproducible code, or communication about missing data evaporates after kickoff.
Why this problem matters — short documentary of recurring failures
Across studies I’ve reviewed, common patterns repeat: underpowered trials, post-hoc endpoint fishing, and opaque handling of dropouts. This is visible at major forums such as the American Gastroenterological Association annual meeting, where protocol-method panels repeatedly highlight mismatches between animal-model variability and analysis plans. Real-world teams running rodent ulcer protocols often need statisticians who understand the models; see Gastric ulcer animal models for the kinds of preclinical work that changes analysis choices. Experience-driven reviews show that early alignment on estimands, randomization, and interim rules prevents nearly all downstream disputes.
Practical checklist: what to verify when evaluating a biostatistics CRO
Ask for concrete evidence: sample analysis plans from past gastroenterology projects, anonymized code (R/SAS) runnable end-to-end, examples of handling missing-not-at-random, and a list of regulatory interactions. Confirm domain knowledge—are they familiar with time-to-event endpoints common in ulcer healing, mixed models for repeated measures, and hierarchical models for multi-site preclinical cohorts? Confirm data pipeline control: can they accept raw lab formats, perform QC, version control analyses, and provide reproducible reports? Set fixed deliverables: an annotated SAP, a reproducible script bundle, and a post-hoc decision log for any deviations.
Common pitfalls teams repeat
They assume any generalist statistician can translate biological nuance into analysis. They accept high-level proposals without reviewing sample code. They ignore stabilization of endpoints (how lesion indices are scored across raters) and delay power discussions until after data collection. They accept amortized hourly estimates without gating milestones for code review. These choices force expensive re-analyses or undermine regulatory credibility.
Alternatives and when to choose them
If you lack internal statistical leadership, a full-service biostatistics CRO that embeds a statistician in the protocol-writing stage is usually better than hiring ad-hoc consultants later. For small pilot studies, consider short-term consultants who deliver a pre-specified SAP and reproducible code; for pivotal trials and regulated submissions, prefer vendors with a demonstrated track record of regulatory interactions and audit-readiness. Open-source collaborations (academic statisticians plus a lab CRO) can work, but expect slower turnarounds and negotiate IP and data governance up front.
The tight logic that solves the problem
Define the problem precisely: list estimands, specify analysis scripts, fix data formats, and require reproducibility evidence up front. Demand examples from relevant models, insist on a timeline that locks statistical milestones before data accrual, and insist on transparent reporting of any post-hoc choices. That combination—hands-on model knowledge, reproducible analytics, and clear milestones—is how a reliable partner organizes work, and it’s the approach embodied by KCI Biotech.